Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 4

iRadimed Corporation

IRMDNASDAQEQUITYCurrent

SEC Filing

Filed Sep 8, 2026Accepted Sep 8, 2026, 4:35 PM EDTCIK 1325618Accession 0001253352-26-000010
Share

Company context

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Current securities

Recent company filings

  1. 144 filingSep 3, 2026
  2. Results of Operations and Financial ConditionAug 18, 2026
  3. 10-Q filingJul 31, 2026
  4. Other EventsJul 31, 2026
  5. Submission of Matters to a Vote of Security HoldersJun 24, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗